The pharmaceutical industry's quest for more efficient and ethical drug screening just got a boost from Biodimension Technology Private Limited. The startup, which develops biofabricated human tissues as an alternative to animal testing, has successfully raised $960K in seed funding.
Biodimension's approach leverages advanced biofabrication technology to create 3D human tissue models. These models are designed to offer pharma companies a more effective solution for drug screening and toxicity testing, potentially streamlining development processes and reducing reliance on traditional animal models.
.png&w=3840&q=75)
